| Hailey Alaine Danielson, MD | |
|
1222 E Woodland Ave, Barron, WI 54812-1765 | |
| (715) 537-3166 | |
| Not Available |
| Full Name | Hailey Alaine Danielson |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 6 Years |
| Location | 1222 E Woodland Ave, Barron, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740778505 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 75224 (Wisconsin) | Primary |
| 207R00000X | Internal Medicine | 75224-20 (Wisconsin) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System-red Cedar Inc | Menomonie, WI | Hospital |
| Mayo Clinic Health System-northland | Barron, WI | Hospital |
| Mayo Clinic Health System Eau Claire Hospital | Eau claire, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-northwest Wisconsin Region Inc | 4385553627 | 623 |
News Archive
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012.
A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.
In the latest research into treating a common childhood cancer, paediatric oncologist Allen Chauvenet, is optimistic that the long-term side effects that survivors experience as they grow into adulthood can be reduced.
Researchers at the University of Rochester Medical Center believe they have identified a new means of enhancing the body's ability to repair its own cells, which they hope will lead to better diagnosis and treatment of traumatic nerve injuries, like those sustained in car accidents, sports injuries, or in combat.
Bracket Global, LLC and Clintara are pleased to announce the two companies have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket's proprietary electronic platform for Clinical Outcome Assessments (eCOA).
› Verified 7 days ago
| Entity Name | Oakleaf Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679870315 PECOS PAC ID: 4486831328 Enrollment ID: O20110602000195 |
News Archive
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012.
A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.
In the latest research into treating a common childhood cancer, paediatric oncologist Allen Chauvenet, is optimistic that the long-term side effects that survivors experience as they grow into adulthood can be reduced.
Researchers at the University of Rochester Medical Center believe they have identified a new means of enhancing the body's ability to repair its own cells, which they hope will lead to better diagnosis and treatment of traumatic nerve injuries, like those sustained in car accidents, sports injuries, or in combat.
Bracket Global, LLC and Clintara are pleased to announce the two companies have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket's proprietary electronic platform for Clinical Outcome Assessments (eCOA).
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20161109002075 |
News Archive
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012.
A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.
In the latest research into treating a common childhood cancer, paediatric oncologist Allen Chauvenet, is optimistic that the long-term side effects that survivors experience as they grow into adulthood can be reduced.
Researchers at the University of Rochester Medical Center believe they have identified a new means of enhancing the body's ability to repair its own cells, which they hope will lead to better diagnosis and treatment of traumatic nerve injuries, like those sustained in car accidents, sports injuries, or in combat.
Bracket Global, LLC and Clintara are pleased to announce the two companies have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket's proprietary electronic platform for Clinical Outcome Assessments (eCOA).
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1154372944 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000001 |
News Archive
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012.
A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.
In the latest research into treating a common childhood cancer, paediatric oncologist Allen Chauvenet, is optimistic that the long-term side effects that survivors experience as they grow into adulthood can be reduced.
Researchers at the University of Rochester Medical Center believe they have identified a new means of enhancing the body's ability to repair its own cells, which they hope will lead to better diagnosis and treatment of traumatic nerve injuries, like those sustained in car accidents, sports injuries, or in combat.
Bracket Global, LLC and Clintara are pleased to announce the two companies have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket's proprietary electronic platform for Clinical Outcome Assessments (eCOA).
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740239557 PECOS PAC ID: 4385553627 Enrollment ID: O20171012000112 |
News Archive
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012.
A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.
In the latest research into treating a common childhood cancer, paediatric oncologist Allen Chauvenet, is optimistic that the long-term side effects that survivors experience as they grow into adulthood can be reduced.
Researchers at the University of Rochester Medical Center believe they have identified a new means of enhancing the body's ability to repair its own cells, which they hope will lead to better diagnosis and treatment of traumatic nerve injuries, like those sustained in car accidents, sports injuries, or in combat.
Bracket Global, LLC and Clintara are pleased to announce the two companies have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket's proprietary electronic platform for Clinical Outcome Assessments (eCOA).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hailey Alaine Danielson, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (715) 838-3635 | Hailey Alaine Danielson, MD 1222 E Woodland Ave, Barron, WI 54812-1765 Ph: (715) 537-3166 |
News Archive
Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its ADASUVE New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2012.
A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.
In the latest research into treating a common childhood cancer, paediatric oncologist Allen Chauvenet, is optimistic that the long-term side effects that survivors experience as they grow into adulthood can be reduced.
Researchers at the University of Rochester Medical Center believe they have identified a new means of enhancing the body's ability to repair its own cells, which they hope will lead to better diagnosis and treatment of traumatic nerve injuries, like those sustained in car accidents, sports injuries, or in combat.
Bracket Global, LLC and Clintara are pleased to announce the two companies have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket's proprietary electronic platform for Clinical Outcome Assessments (eCOA).
› Verified 7 days ago